Skip to main content
. 2023 Aug 29;14:158. doi: 10.1007/s12672-023-00774-4

Fig. 1.

Fig. 1

Kaplan–Meier curves of overall survival (a) and progression-free survival (b) for patients after chemotherapy following immune checkpoint inhibitor therapy. The median OS was 10 months (95% CI 6–18), and the estimated 12-month OS rate was 44.5% (a). The median PFS was 5 months (95% CI 4–6), and the 12-month PFS estimate was 8.9%